Symptom return can impact your patients in many ways.
Consider prescribing INBRIJA—an on-demand inhaled levodopa medication that complements baseline therapy to improve symptoms when needed for patients treated with carbidopa/levodopa (CD/LD).
For US Healthcare Professionals
Consider prescribing INBRIJA—an on-demand inhaled levodopa medication that complements baseline therapy to improve symptoms when needed for patients treated with carbidopa/levodopa (CD/LD).
INBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.
Please see the Full Prescribing Information.
INBRIJA is contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to risk of hypertension.
Patients treated with levodopa have reported falling asleep during activities of daily living, including operation of motor vehicles, which